Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Common Equity (2016 - 2025)

Alterity Therapeutics has reported Common Equity over the past 5 years, most recently at $11.6 million for Q2 2019.

  • For Q2 2019, Common Equity fell 4.75% year-over-year to $11.6 million; the TTM value through Jun 2019 reached $11.6 million, down 4.75%, while the annual FY2019 figure was $11.6 million, 4.75% down from the prior year.
  • Common Equity for Q2 2019 was $11.6 million at Alterity Therapeutics, up from $7.8 million in the prior quarter.
  • Over five years, Common Equity peaked at $110.7 million in Q4 2017 and troughed at $7.8 million in Q4 2018.
  • A 5-year average of $38.9 million and a median of $23.4 million in 2016 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: soared 321.99% in 2016 and later tumbled 92.92% in 2018.
  • Year by year, Common Equity stood at $26.1 million in 2015, then surged by 321.99% to $110.1 million in 2016, then rose by 0.54% to $110.7 million in 2017, then tumbled by 92.92% to $7.8 million in 2018, then skyrocketed by 47.98% to $11.6 million in 2019.
  • Business Quant data shows Common Equity for ATHE at $11.6 million in Q2 2019, $7.8 million in Q4 2018, and $12.2 million in Q2 2018.